Kabi Pharmacia Ab

Upjohn Stockholders OK Merger With Pharmacia: Upjohn Co. stockholders approved a merger with Swedish drug maker Pharmacia, as expected, moving the proposed combination one step closer to completion. Separately, Upjohn reported third-quarter income from continuing operations rose 4% to $133 million as sales grew 3% to $831 million from the 1994 quarter.

Upjohn Stockholders OK Merger With Pharmacia: Upjohn Co. stockholders approved a merger with Swedish drug maker Pharmacia, as expected, moving the proposed combination one step closer to completion. Separately, Upjohn reported third-quarter income from continuing operations rose 4% to $133 million as sales grew 3% to $831 million from the 1994 quarter.

McGaw Inc., a supplier of intravenous products, announced Tuesday that it has sold licensing rights to a Swedish medical supply company to manufacture and distribute an environmentally safe IV solution bag in Europe. The licensing deal with Kabi Pharmacia AB of Stockholm is expected to generate $10 million in income for the Irvine-based company over the next five years, McGaw officials said.

Genentech Inc. shares fell Thursday after a leading medical journal said the firm's heart attack drug is only slightly more effective than a far cheaper alternative and should only be used on a limited basis. A House subcommittee was also reported to be looking into a major 1993 study finding that the genetically engineered tPA, sold as Activase, is superior to the alternative treatment, streptokinase, which costs about one-tenth as much. Genentech shares fell $1.125 to $45.

McGaw Inc. has struck a deal with Du Pont Merck to jointly market a chemical solution to increase plasma volume during surgery while reducing the risk of infection from contaminated blood products. In a bonus for McGaw, Du Pont Merck has also agreed to market the solution in an environmentally safe intravenous bag developed by McGaw, company officials said Friday.